The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretmm

Basit Öğe Kaydı
dc.authoridTurkmen, Samdanci, Emine/0000-0002-0034-5186
dc.authoridÇOLAK, CEMİL/0000-0001-5406-098X
dc.authoridÇelik, Muhammet Reha/0000-0001-8461-2909
dc.authoridAKATLI, AYSE NUR/0000-0002-9677-2456
dc.authoridUlutas, Hakki/0000-0001-9603-7323
dc.authoridSahin, Nurhan/0000-0002-5039-1164
dc.authorwosidTurkmen, Samdanci, Emine/ABH-4716-2020
dc.authorwosidUlutas, Hakki/ABH-8162-2020
dc.authorwosidÇOLAK, CEMİL/ABI-3261-2020
dc.authorwosidÇelik, Muhammet Reha/AAZ-4455-2020
dc.authorwosidAKATLI, AYSE NUR/ABH-4455-2020
dc.authorwosidUlutas, Hakki/AAS-3954-2020
dc.contributor.authorSahin, Nurhan
dc.contributor.authorAkatli, Ayse Nur
dc.contributor.authorCelik, Muhammet Reha
dc.contributor.authorUlutas, Hakki
dc.contributor.authorSamdanci, Emine Turkmen
dc.contributor.authorColak, Cemil
dc.date.accessioned2024-08-04T20:42:42Z
dc.date.available2024-08-04T20:42:42Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPleural Malignant Mesothelioma (MM) is a fatal disease that has been associated with asbestos exposure. Differential diagnosis between the pleural infiltration of pulmonary carcinomas and MM is rather difficult particularly for epitheloid type mesothelioma. We aimed to investigate the utility of CD90, a cancer stem cell marker, in the differential diagnosis of MM and lung carcinoma, its prognostic significance and compare its value with that of Calretinin. Ninety pathology specimens including MM (n:30), pulmonary adenocarcinoma (n:30) and pulmonary squamous cell carcinoma (n:30) were used in this study. Immunohistochemical comparision of CD 90 and Calretinin was made in all groups. Calretinin was positive in 20 cases with MM (64.5 %), and was negative in 10 (32.3 %). CD 90 was positive in 25 of these cases (80 %) and negative in 5 (16 %). On the other hand pulmonary adenocarcinomas and squamous cell carcinomas showed positivity with CD90, 63,6 % and 73 %, respectively. We think that CD 90 has no place in the differential diagnosis between mesothelioma and pulmonary carcinoma because of the low specificity in spite of the high sensitivity.en_US
dc.identifier.doi10.1007/s12253-016-0135-9
dc.identifier.endpage491en_US
dc.identifier.issn1219-4956
dc.identifier.issn1532-2807
dc.identifier.issue3en_US
dc.identifier.pmid27761727en_US
dc.identifier.scopus2-s2.0-84991824584en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage487en_US
dc.identifier.urihttps://doi.org/10.1007/s12253-016-0135-9
dc.identifier.urihttps://hdl.handle.net/11616/97541
dc.identifier.volume23en_US
dc.identifier.wosWOS:000402570200004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofPathology & Oncology Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMesotheliomaen_US
dc.subjectCD 90en_US
dc.subjectPulmonary adenocarcinomaen_US
dc.subjectSquamous cell carcinomaen_US
dc.titleThe Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretmmen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu